Evidence map›Paper›PMID 31058103›Full record

ArticleFrontiers in cellular and infection microbiology2019

Editorial: The Pathogenic Yersiniae-Advances in the Understanding of Physiology and Virulence, Second Edition.

Matthew S Francis, Victoria Auerbuch

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Matthew S FrancisDepartment of Molecular Biology, Umeå Centre for Microbial Research, Umeå University, Umeå, Sweden.
Victoria AuerbuchDepartment of Microbiology and Environmental Toxicology, University of California, Santa Cruz, Santa Cruz, CA, United States.

Funding

Development of validated probes for the bacterial type III secretion systemR01AI141511 · NIAID · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI STONE, VICTORIA AUERBUCH · 2019 to 2022
$3.0M
Host iron and Yersinia pathogenesisR01AI119082 · NIAID · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI STONE, VICTORIA AUERBUCH · 2016 to 2020
$2.5M
Innate immunity-based screen for bacterial type III secretion system inhibitorsR01AI106930 · NIAID · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI STONE, VICTORIA AUERBUCH · 2014 to 2016
$1.2M
NIAID NIH HHS R01 AI106930NIAID NIH HHS R01 AI119082NIAID NIH HHS R01 AI141511
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsBiomedical ResearchHumansVirulenceYersinia enterocoliticaYersinia InfectionsYersinia pestisYersinia pseudotuberculosisbiofilmCrohn's diseasefish- and insect-pathogenphenotypic and niche adaptationprotein secretionsmall regulatory RNAstwo-component systemsvirulence blockers

Identifiers

PMID31058103
PMCPMC6482262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.